S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

STRO Sutro Biopharma Inc

2.04

0.00 (0.00%)

Pre Market

Last Updated: 23:01:41

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

01/29/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

06/29/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Nicki Jean Vasquez

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Sutro Biopharma (NASDAQ:STRO)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Sutro Biopharma Charts.

Sutro Biopharma (NASDAQ:STRO)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Sutro Biopharma Charts.

Sutro Biopharma Inc News

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Wednesday 8 January 2025 (3 weeks ago) • GlobeNewswire Inc.

Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale
Wednesday 8 January 2025 (3 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Wednesday 11 December 2024 (2 months ago) • Edgar (US Regulatory)

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer
Wednesday 11 December 2024 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 4 December 2024 (2 months ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 15 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 14 November 2024 (2 months ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Thursday 14 November 2024 (2 months ago) • Edgar (US Regulatory)

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
Thursday 14 November 2024 (2 months ago) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Wednesday 13 November 2024 (2 months ago) • Edgar (US Regulatory)

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference
Tuesday 5 November 2024 (3 months ago) • GlobeNewswire Inc.

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
Friday 1 November 2024 (3 months ago) • GlobeNewswire Inc.

More Sutro Biopharma Inc News Articles

Westpac Banking

Commonwealth Bank Of Aus...

Gold vs US Dollar

Verizon Communications

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions